The Anticancer Activity and HSA Binding Properties of the Structurally Related Platinum (II) Complexes

The development of resistance and unwanted harmful interaction with other biomolecules instead of DNA are the major drawbacks for application of platinum (Pt) complexes in cancer chemotherapy. To conquer these problems, much works have been done so far to discover innovative Pt complexes. The objective of the current study was to evaluate the anti cancer activities of a series of four and five-coordinated Pt(II) complexes, having deprotonated 2-phenyl pyridine (abbreviated as C^N), biphosphine moieties, i.e., dppm?=?bis(diphenylphosphino) methane (Ph₂PCH₂PPh₂) and dppa?=?bis(diphenylphosphino)amine (Ph₂PNHPPh₂), as the non-leaving carrier groups. The growth inhibitory effect of the Pt complexes [Pt(C^N)(dppm)]PF₆: C ₁ , [Pt(C^N)(dppa)]PF₆: C ₂ , and [Pt(C^N)I(dppa)]: C ₃ , toward the cancer cell lines was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. In addition, the florescence quenching experiments of the interaction between human serum albumin (HSA) and the Pt complexes were performed in order to obtain the binding parameters and to evaluate the denaturing properties of these complexes upon binding to the general carrier protein of blood stream. The structure?Cactivity relationship studies reveal that four-coordinated Pt complexes C ₁ and C ₂ with both significant hydrophobic and charge characteristics, not only exhibit strong antiproliferation activity toward the cancer cell lines, but also they display lower denaturing effect against carrier protein HSA. On the other hand, five-coordinated C ₃ complex with the unusual intermolecular NH??Pt hydrogen binding and the intrinsic ability for oligomerization, exhibits poor anticancer activity and strong denaturing property. The current study reveals that the balance between charge and hydrophobicity of the Pt complexes, also their hydrogen binding abilities and coordination mode are important for their anticancer activities. Moreover, this study may suggest C ₁ and C ₂ as the potential template structures for synthesis of new generation of four-coordinated Pt complexes with strong anticancer activities and weak denaturing effects against proteins.     

Mass Spectrometric Strategies to Improve the Identification of Pt(II)-Modification Sites on Peptides and Proteins

To further explore the binding chemistry of cisplatin (cis-Pt(NH₃)₂Cl₂) to peptides and also establish mass spectrometry (MS) strategies to quickly assign the platinum-binding sites, a series of peptides with potential cisplatin binding sites (Met(S), His(N), Cys(S), disulfide, carboxyl groups of Asp and Glu, and amine groups of Arg and Lys, were reacted with cisplatin, then analyzed by electron capture dissociation (ECD) in a Fourier transform ion cyclotron resonance mass spectrometer (FT-ICR MS). Radical-mediated side-chain losses from the charge-reduced Pt-binding species (such as CH₃S^? or CH₃SH from Met, SH^? from Cys, CO₂ from Glu or Asp, and NH₂ ^? from amine groups) were found to be characteristic indicators for rapid and unambiguous localization of the Pt-binding sites to certain amino acid residues. The method was then successfully applied to interpret the top-down ECD spectrum of an inter-chain Pt-crosslinked insulin dimer, insulin?+?Pt(NH₃)₂?+?insulin (>10 kDa). In addition, ion mobility MS shows that Pt binds to multiple sites in Substance P, generating multiple conformers, which can be partially localized by collisionally activated dissociation (CAD). Platinum(II) (Pt(II)) was found to coordinate to amine groups of Arg and Lys, but not to disulfide bonds under the conditions used. The coordination of Pt to Arg or Lys appears to arise from the migration of Pt(II) from Met(S) as shown by monitoring the reaction products at different pH values by ECD. No direct binding of cisplatin to amine groups was observed at pH 3?~?10 unless Met residues were present in the sequence, but noncovalent interactions between cisplatin hydrolysis and amination [Pt(NH₃)₄]²⁺ products and these peptides were found regardless of pH.

Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC–ICP–MS

A high-performance liquid chromatography–inductively coupled plasma mass spectrometry (HPLC–ICP–MS) method is presented for analysis of cisplatin, monoaquacisplatin, diaquacisplatin, carboplatin, and oxaliplatin in biological and environmental samples. Chromatographic separation was achieved on pentafluorophenylpropyl-functionalized silica gel. For cisplatin, carboplatin, and oxaliplatin limits of detection of 0.09, 0.10, and 0.15 g L^–1, respectively, were calculated at m/z 194, using aqueous standard solutions. (3 L injection volume). The method was utilized for model experiments studying the stability of carboplatin and oxaliplatin at different chloride concentrations simulating wastewater and surface water conditions. It was found that a high fraction of carboplatin is stable in ultrapure water and in solutions containing 1.5 mol L^–1 Cl^–, whereas oxaliplatin degradation was increased by increasing the chloride concentration. In order to support the assessment of oxaliplatin eco-toxicology, the method was tested for speciation of patient urine. The urine sample contained more than 17 different reaction products, which demonstrates the extensive biotransformation of the compound. In a second step of the study the method was successfully evaluated for monitoring cancerostatic platinum compounds in hospital waste water.     

Complexes of platinum and palladium with 4-nitrobenzoic hydrazide: synthesis and cytotoxic activity

New complexes of platinum and palladium were isolated with 4-nitrobenzoic hydrazide (4-NH) and characterized by spectroscopic techniques. Results show that the ligand is coordinated to metallic ions by the basic nitrogen of NH₂ group and have the general structure cis-[M(4-NH)₂X₂] where M= Pt or Pd and x = Cl or I. The compound III, [Pt(4-NH)₂I₂], was found to display cytotoxicity (IC₅₀ = 0.96 μmol L^?1) against the K562 tumoral cell line. This complex is significantly more cytotoxic than cisplatin.      

MALDI-Q-TOF mass spectrometric determination of gold and platinum in tissues using their diethyldithiocarbamate chelate complexes

A rapid determination method is presented for gold (Au³⁺) and platinum (Pt⁴⁺) in tissues using matrix-assisted laser desorption ionization quadrupole time-of-flight mass spectrometry (MALDI-Q-TOF-MS). Au and Pt ions in wet-ashed tissue solution were reacted with diethyldithiocarbamate (DDC), and the resulting chelate complex ions Au(DDC)₂ ⁺ and Pt(DDC)₃ ⁺ were detected by MALDI-Q-TOF-MS using α-cyano-4-hydroxycinnamic acid as a matrix. The limit of detection (LOD) was 0.8 ng/g tissue and the quantification range was 2–400 ng/g for Au, and the LOD was 6 ng/g tissue and the quantification range was 20–4,000 ng/g for Pt. The Pt levels detected by MALDI-Q-TOF-MS in several tissues of a patient overdosed with cisplatin were nearly the same as those detected by flow-injection electrospray ionization mass spectrometry. The LODs of Au and Pt were 0.04 pg per well (sample spot) and 0.3 pg per well, respectively. To our knowledge, this is the first attempt to quantify Au³⁺ and Pt⁴⁺ ions in tissues by MALDI-Q-TOF-MS.

A shotgun approach for the identification of platinum–protein complexes

A shotgun approach including peptide-based OFFGEL-isoelectric focusing (IEF) fractionation has been developed with the aim of improving the identification of platinum-binding proteins in biological samples. The method is based on a filter-aided sample preparation (FASP) tryptic digestion under denaturing and reducing conditions of cisplatin–, oxaliplatin–, and carboplatin–protein complexes, followed by OFFGEL-IEF separation of the peptides. Any risk of platinum loss is minimized throughout the procedure due to the removal of the reagents used after each stage of the FASP method and the absence of thiol-based reagents in the focusing buffer employed in the IEF separation. The platinum–peptide complexes stability after the FASP digestion and the IEF separation was confirmed by size exclusion chromatography-inductively coupled plasma-mass spectrometry (SEC-ICP-MS). The suitability of peptide-based OFFGEL-IEF fractionation for reducing the sample complexity for further nano-liquid chromatography-electrospray ionization-tandem mass spectrometry (nLC-ESI-MS/MS) analysis has been demonstrated, allowing the detection of platinum-containing peptides, with significantly lower abundance and ionization efficiency than unmodified peptides. nLC-MS/MS analysis of selected OFFGEL-IEF fractions from tryptic digests with different complexity degrees: standard human serum albumin (HSA), a mixture of five proteins (albumin, transferrin, carbonic anhydrase, myoglobin, and cytochrome-c) and human blood serum allowed the identification of several platinum–peptides from cisplatin–HSA. Cisplatin-binding sites in HSA were elucidated from the MS/MS spectra and assessed considering the protein three-dimensional structure. Most of the potential superficial binding sites available on HSA were identified for all the samples, including a biologically relevant cisplatin-cross-link of two protein domains, demonstrating the capabilities of the methodology.

Open image in new window

Graphical Abstract Graphical abstract shows the several steps involved in the identification of platinum-protein complexes: FASP digestion of proteins, peptide fractionation by OFFGEL-IEF and identification of Pt-complexes by nLC-ESIMS/MS

     

Study on the interaction of three structurally related cationic Pt(II) complexes with human serum albumin: importance of binding affinity and denaturing properties

Human serum albumin (HSA) primarily functions as a transport carrier for a vast variety of natural ligands and pharmaceutical drugs. In the present study, three structurally related cationic Pt(II) complexes ([Pt(ppy)(dppe)]CF₃CO₂: 1, Pt(bhq)(dppe)]CF₃CO₂: 2, and [Pt(bhq)(dppf)]CF₃CO₂: 3) were used to evaluate their interaction with HSA under different experimental setups, using UV–Vis absorption spectroscopy, fluorescence and circular dichroism techniques. The spectroscopic results suggest that upon binding to HSA, the Pt(II) complexes could effectively induce structural alteration of the protein. The complexes can bind to HSA with the binding affinities of the following order: 3 > 2 > 1. Also, thermodynamic parameters of binding between these complexes and HSA indicated the existence of entropy-driven spontaneous interaction which primarily dominated with the hydrophobic forces. Also, docking simulation study revealed the binding details of these complexes on HSA. Complex 3 with highest binding affinity for HSA indicates lowest denaturing effect on this protein. The low denaturation properties of 3 appear important in the terms of lower susceptibility of this platinum complex for possible development of deleterious side effects.     

Synthesis of lanthanide(III) complexes appended with a diphenylphosphinamide and their interaction with human serum albumin

Two DOTA-based proligands bearing a pendant diphenylphosphinamide 4a and 4b were synthesised. Their Eu(III) complexes exhibit sensitised emission when excited at 270 nm via the diphenylphosphinamide chromophore. Hydration states of q = 1.5 were determined from excited state lifetime measurements (Eu.4a $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 2. 1 4 \,{\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 0. 6 4 \,{\text{ms}}^{ - 1} $ ; Eu.4b $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 2. 6 7\, {\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 1. 1 8 \,{\text{ms}}^{ - 1} $ ). In the presence of human serum albumin (HSA) (0.1 mM Eu.4a/b, 0.67 mM HSA, pH 7.4) q = 0.4 for Eu.4a ( $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 1. 3 4\, {\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 0. 7 5\, {\text{ms}}^{ - 1} $ ) and q = 0.6 for Eu.4b ( $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 1. 8 3\, {\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 1.0 5 \,{\text{ms}}^{ - 1} $ ). Relaxivites (pH 7.4, 298 K, 20 MHz) of the Gd(III) complexes in the absence and presence of HSA (0.1 mM Gd.4a/b, 0.67 mM HSA) were: Gd.4a (r ₁ = 7.6 mM^?1s^?1 and r ₁ = 11.7 mM^?1s^?1) and Gd.4b. (r ₁ = 7.3 mM^?1s^?1 and r ₁ = 16.0 mM^?1s^?1). These relatively modest increases in r ₁ are consistent with the change in inner-sphere hydration on binding to HSA shown by luminescence measurements on Eu.4a/b. Binding constants for HSA determined by the quenching of luminescence (Eu) and enhancement of relaxivity (Gd) were Eu.4a (27,000 M^?1 ± 12%), Eu.4b (32,000 M^?1 ± 14%), Gd.4a (21,000 M^?1 ± 15%) and Gd.4b (26,000 M^?1 ± 15%).     

Thermal and spectral studies of palladium(II) and platinum(IV) complexes with dithiocarbamate derivatives

Four new coordination complexes of palladium(II) and platinum(IV) starting from bis(dimethylthiocarbamoyl)sulphide (L¹) and bis(diethylthiocarbamoyl)disulphide (L²) were synthesized and characterized in solid state by elemental analysis, infrared and electronic spectroscopy as well as thermal analysis (TG/DTA). The complexes were formulated on the basis of experimental data as [Pd(Me₂NCS₂)₂] (1), [Pt(Me₂NCS)₂SCl₄]·3H₂O (2), [Pd(Et₂NCS₂)₂] (3) and [Pt(Et₂NCS)₂S₂Cl₄]·4H₂O (4), respectively. TG experiments revealed the nature of complex species as hydrated (2 and 4) or anhydrous (1 and 3). Thermal decomposition of coordinated organic ligands occurs in one or two exothermic stages, the final residue being in all cases the free metal (Pd or Pt).     

Synthesis and characterization of palladium(II) and platinum(II) metal complexes with iminophosphine ligands: X-ray crystal structures of platinum(II) complexes and use of palladium(II) complexes as pre-catalysts in Heck and Suzuki cross-coupling reactions

The reactions of N-(2(diphenylphosphino) benzylidene) (phenyl) methanamine, Ph₂PPhNHCH₂-C₅H₄N, 1 and N-(2-(diphenylphosphino) (benzylidene) (thiophen-2-yl) methanamine, Ph₂PPhNHCH₂-C₄H₃S, 2 with MCl₂(cod) and MCl(cod)Me (M = Pd, Pt; cod = 1,5-cyclooctadiene) yield the new complexes [M(Ph₂PPhNHCH₂-C₅H₄N)Cl₂], M = Pd1a, Pt1b, [M(Ph₂PPhNHCH₂-C₅H₄N)ClMe], M = Pd1c, Pt 1d, [M(Ph₂PPhNHCH₂-C₄H₃S)Cl₂], M = Pd2a, Pt 2b, and [M(Ph₂PPhNHCH₂-C₄H₃S)ClMe], M = Pd2c, Pt 2d, respectively. The new compounds were isolated as analytically pure crystalline solids and characterized by ³¹P-, ¹H-NMR, IR spectroscopy, electro spray ionization-mass spectrometry (ESI-MS) and elemental analysis. The representative solid-state molecular structures of the platinum complexes 1b and 2b were determined using single crystal X-ray diffraction analysis and revealed that the complexes exhibit a slightly distorted square-planar geometry. Furthermore, the palladium complexes were tested as potential catalysts in the Heck and Suzuki cross-coupling reactions.     

Use of entrapment and high-performance affinity chromatography to compare the binding of drugs and site-specific probes with normal and glycated human serum albumin

Protein entrapment and high-performance affinity chromatography were used with zonal elution to examine the changes in binding that occurred for site-specific probes and various sulfonylurea drugs with normal and glycated forms of human serum albumin (HSA). Samples of this protein in a soluble form were physically entrapped within porous silica particles by using glycogen-capped hydrazide-activated silica; these supports were then placed into 1.0 cm × 2.1 mm inner diameter columns. Initial zonal elution studies were performed using (R)-warfarin and l-tryptophan as probes for Sudlow sites I and II (i.e., the major drug binding sites of HSA), giving quantitative measures of binding affinities in good agreement with literature values. It was also found for solutes with multisite binding to the same proteins, such as many sulfonylurea drugs, that this method could be used to estimate the global affinity of the solute for the entrapped protein. This entrapment and zonal approach provided retention information with precisions of ±0.1–3.3% (± one standard deviation) and elution within 0.50–3.00 min for solutes with binding affinities of 1?×?10⁴–3?×?10⁵ M^?1. Each entrapped-protein column was used for many binding studies, which decreased the cost and amount of protein needed per injection (e.g., the equivalent of only 125–145 pmol of immobilized HSA or glycated HSA per injection over 60 sample application cycles). This method can be adapted for use with other proteins and solutes and should be valuable in high-throughput screening or quantitative studies of drug–protein binding or related biointeractions.

Glutathione modified CdTe quantum dots as a label for studying DNA interactions with platinum based cytostatics

Cisplatin, carboplatin, and oxaliplatin represent three generations of platinum based drugs applied successfully for cancer treatment. As a consequence of the employment of platinum based cytostatics in the cancer treatment, it became necessary to study the mechanism of their action. Current accepted opinion is the formation of Pt‐DNA adducts, but the mechanism of their formation is still unclear. Nanomaterials, as a progressively developing branch, can offer a tool for studying the interactions of these drugs with DNA. In this study, fluorescent CdTe quantum dots (QDs, λ_em = 525 nm) were employed to investigate the interactions of platinum cytostatics (cisplatin, carboplatin, and oxaliplatin) with DNA fragment (500 bp, c = 25 μg/mL). Primarily, the fluorescent behavior of QDs in the presence of platinum cytostatics was monitored and major differences in the interaction of QDs with tested drugs were observed. It was found that the presence of carboplatin (c = 0.25 mg/mL) had no significant influence on QDs fluorescence; however cisplatin and oxaliplatin quenched the fluorescence significantly (average decrease of 20%) at the same concentration. Subsequently, the amount of platinum incorporated in DNA was determined by QDs fluorescence quenching. Best results were reached using oxaliplatin (9.4% quenching). Linear trend (R² = 0.9811) was observed for DNA platinated by three different concentrations of oxaliplatin (0.250, 0.125, and 0.063 mg/mL). Correlation with differential pulse voltammetric measurements provided linear trend (R² = 0.9511). As a conclusion, especially in the case of oxaliplatin‐DNA adducts, the quenching was the most significant compared to cisplatin and nonquenching carboplatin.     

Electrochemical synthesis of a novel platinum nanostructure on a glassy carbon electrode, and its application to the electrooxidation of methanol

We show that the addition of white dextrin during the electrochemical deposition of platinum nanostructures (nano-Pt) on a glassy carbon electrode (GCE) results in an electrochemically active surface that is much larger than that of platinum microparticles prepared by the same procedure but in the absence of dextrin. The nano-Pt deposits are characterized by scanning electron microscopy (SEM), energy dispersive spectroscopy, and electrochemical methods. The SEM images reveal deposits composed of mainly nanoparticles and short nanorods. The GCE was applied as a novel and cost-effective catalyst for methanol oxidation. The use of nano-Pt improves the electrocatalytic activity and the stability of the electrodes.

Characterization of the interaction between a platinum(II) complex and human serum albumin: spectroscopic analysis and molecular docking

In this study, the interaction between (2,2?-bipyridine)(pyrrolidinedithiocarbamato) platinum(II) nitrate, [Pt(bpy)(pyr-dtc]NO₃, and human serum albumin (HSA) was investigated by various spectroscopic methods (UV–vis, fluorescence, CD and FT-IR) and molecular docking technique at three temperatures. UV–vis absorption spectroscopy showed that Pt(II) complex can denature the protein at moderate concentrations. The results of emission quenching at two temperatures has revealed that the quenching mechanism of Pt(II) complex with HSA was static quenching mechanism. Binding constants (K), binding site number (n) and corresponding thermodynamic parameters ?G?, ?H? and ?S? were calculated and revealed that hydrophobic forces played a major role when Pt(II) complex interacted with HSA. The binding distance (r) between above complex and HSA based on Förster?s theory of non-radiation energy transfer was calculated as 3.22 nm. Alterations of HSA secondary structure induced by complex were confirmed by FT-IR and CD measurements. Also, a molecular docking study was performed for identification of key structural features of binding of the Pt complex into the receptor and predicting bioactive conformers. Our results may provide valuable information to understand the mechanistic pathway of drug delivery and to pharmacological behavior of drug.     

Oxidation of coordinated ethylenediamine in platinum(IV) complexes with bromine. Crystal structures of [Pt(en)Py2Br2]Br2 · H2O, [Pt(HN-C(O)-C(O)-NH)Py2Br2] · H2O, and [Pt(en)PyBr3]NO3

Heating of an aqueous solution of [Pt(en)Py₂Cl₂]Cl₂ · 2H₂O (I) with KBr excess leads to the formation of [Pt(en)Py₂Br₂]Br₂ · H₂O (II). The interaction of a solution of II with bromine water results in the precipitation of polybromide ([Pt(en)Py₂Br₂]Br₂ · Br₂), which within a few days in the reaction solution partly transforms into oximide platinum(IV) complex, [Pt(HN-C(O)-C(O)-NH)Py₂Br₂] · H₂O (III). Complex [Pt(en)PyBr₃]Br · H₂O (IV) with an impurity of II was prepared by reacting KBr excess and the product of [Pt(en)Py₂]Cl₂ oxidation with chlorine in 0.05 N HCl. The action of HNO₃ on the solution of IV produced a nitrate derivative ([Pt(en)PyBr₃]NO₃, V). Complex IV, unlike II, does not react with bromine. The IR spectra of all the obtained compounds were recorded. Complexes II, III, and V were studied by X-ray crystallography. The crystals of II are monoclinic, space group P2₁/c, a = 15.640(2) Å, b = 9.345(1) Å, c = 14.167(2) Å, β = 102.63(1)°, V = 2020.5(5) ų, Z = 4, R _hkl = 0.033. The crystals of III are triclinic, space group P $\bar 1$ , a = 7.108(1) Å, b = 10.946(1) Å, c = 11.020(2) Å, α = 83.63(1)°, β = 80.31(1)°, γ = 75.02(1)°, V = 814.4(2) ų, Z = 2, R _hkl = 0.033. In the near-planar five-membered chelate ring (torsion angle NCCN is 7°), the C-O distances (1.23(1) Å) correspond to double bonds; the C-C (1.53(1) Å) and C-N (1.31(1) Å), distances correspond to ordinary bonds. The crystals of V are monoclinic, space group P2₁/c, a = 8.306(2) Å, b = 8.995(2) Å, c = 20.231(4) Å, β = 97.48(2)°, V = 1498.6(6) ų, Z = 4, R _hkl = 0.037.     

Platinum(II) cyclo-hexamethylenedithiocarbamate complex, [Pt{S2CN(CH2)6}2] and its solvated form, [Pt{S2CN(CH2)6}2] · CHCl3: Crystal and molecular structures, 13C CP/MAS NMR data, and thermal behavior

Platinum(II) cyclo-hexamethylenedithiocarbamate (HmDtc) complex, [Pt{S₂CN(CH₂)₆}₂] (I), and its solvated form, Pt{S₂CN(CH₂)₆}₂] · CHCl₃ (II), are synthesized and characterized by the ¹³C MAS NMR data. The HmDtc ligands in structure I are not equivalent, whereas the solvation of the complex is accompanied by the structural unification of the initially nonequivalent HmDtc ligands. In addition, the spectra are characterized by the ¹³C-¹⁹⁵Pt spin-spin coupling. The noncentrosymmetric molecular structure of compound I determined by X-ray diffraction analysis includes two nonequivalent dithiocarbamate ligands coordinated by the metal in the S,S′-bidentate mode. The central atom forming the [PtS₄] chromophore (intraorbital dsp ²-hybrid state of platinum) shifts from the plane of four sulfur atoms by 0.07 Å in the vertex of the flattened tetragonal pyramid. The seven-membered heterocycles ?N(CH₂)₆ of the HmDtc ligands are oppositely directed in space relative to the [S₄] plane (trans orientation). The thermal behavior of compounds I and II are studied by simultaneous thermal analysis. In both cases, the final product of the multistage thermal destruction of the complexes is reduced metallic platinum.     

A kinetic analysis of oxidation of the antioxidant <Emphasis Type="Italic">N</Emphasis>-acetyl-<Emphasis Type="SmallCaps">l</Emphasis>-cysteine (NAC) by Pt(IV) complexes

N-acetyl-l-cysteine (NAC) is an antioxidant and a supplement and has been demonstrated to have protective effects for a variety of toxic effects of heavy metals. Although previous works have shown that NAC can ameliorate the severe toxic effects of cisplatin, there is a lack of understanding of the interactions between NAC and Pt(IV)-based prodrugs. In this work, the oxidation of NAC by a cisplatin prodrug (cis-[Pt(NH₃)₂Cl₄]), by a prototype of Pt(IV) anticancer drug ormaplatin ([Pt(dach)Cl₄]) and by a model compound (trans-[PtCl₂(CN)₄]^2–) was characterized in detail. NAC was oxidized to NAC-disulfide as identified by mass spectrometric analysis. Time-resolved spectral and stopped-flow kinetic measurements were carried out over a wide pH range, demonstrating that the oxidation followed overall second-order kinetics. The observed second-order rate constants k′ versus pH profiles were established. A reaction mechanism was deduced, involving three parallel rate-determining steps; conceivable transition states were also proposed for these steps. Rate constants of the rate-determining steps, obtained from the simulations of rate equation to the k′–pH profiles, were largely correlated with the electron density on the sulfur atom in NAC. The Pt(IV) prodrugs can execute oxidative stress in the biological systems of the human body by direct oxidation of relevant molecules, similar to HOCl/OCl^? and chloroamines. Instead, the oxidative stress involved in the severe toxic effects of cisplatin is produced via a different mode. NAC could be a chemoprotecting agent also for the Pt(IV) anticancer drugs if recent drug delivery technologies are used.     

Mixed-ligand platinum(IV) complexes with amino acids and cytosine

Complex formation in platinum(IV)-cytosine-amino acid (glycine, α-alanine, lysine, or histidine) systems is studied using pH titration. Stability constants for 1:1:1 stoichiometry of complexes are determined. The stability of the mixed-ligand complexes varies in the following order: Lys < Ala < Gly < His. Reactions of aqueous solutions yields the following complexes: Pt(Cyt)(Gly^?)Cl₃ · 3H₂O (I), pt(Cyt)(Ala^?)Cl₃ · 3H₂O (II), Pt(Cyt)(Hist)Cl₄ · 2H₂O (III), and Pt(Cyt)(Lys)Cl₄ · 2H₂O (IV). ¹³C NMR, IR, and XPS spectra show that glycine and alanine are complexed via amino and carboxy groups, lysine via its α-amino group exclusively, and histidine via its amino group and heterocyclic N3 atom. Cytosine in these complexes is bidentate (it is complexed via C=O oxygen and N3 heterocyclic atoms).     

Stannylene complexes of manganese,iron, and platinum

A number of stannylene complexes with different M: Sn ratios were obtained using various metals and substituents at the tin atom. The structures of the complexes were examined. A reaction of CpMn(CO)₂THF with (Ph₄As)⁺(SnCl₃)^? gave the ionic complex [Ph₄As]⁺[CpMn(CO)₂SnCl₃]^? (I). The action of C₆F₅MgBr on the complex C₅H₅Mn(CO)(NO)SnCl₃ produced C₅H₅Mn(CO)(NO)Sn(C₆F₅)₃ (II). Replacement of the Cl ions in the complex [CpFe(CO)₂]₂SnCl₂ by phenylacetylenide groups gave rise to the neutral complex [CpFe(CO)₂]₂Sn(C≡CPh)₂ (III). A reaction of (Dppm)PtCl₂ (Dppm is 1,1-bis(diphenylphosphino)methane) with SnCl₂ · 2H₂O in the presence of diglyme yielded the ionic complex [η³-CH₃O(CH₂)₂O(CH₂)₂OCH₃)SnCl]⁺[(η ²-Dppm)Pt(SnCl₃)₃]^? (IV). Transmetalation in a reaction of [(Dppe)₂CoCl][SnCl₃] · PhBr (Dppe is 1,2-bis(diphenylphosphino)ethane) with (Dcpd)PtCl₂ (Dcpd is dicyclopentadiene) in the presence of SnCl₂ afforded the ionic complex [Pt(Dppe)₂]₃[Pt(SnCl₃)₅]₂ (V). Structures I–V were identified by X-ray diffraction. In these structures, the formally single bonds between the atoms of transition metals M (Mn, Fe, and Pt) and Main Group heavy elements (Sn and P) having vacant d orbitals are appreciably shortened. The M-Sn bond length in complexes II and III are virtually independent of the substituents at the tin atom and the Pt-Sn bond length in complexes IV and V is virtually independent of the Pt: Sn ratio.